[s1artibartfast]

You would still have to raise several hundred millions of dollars of funding to reconduct development and clinical trials for the drug after securing the IP.

Clinical trial data and manufacturing know how cant be leveraged from the original approval.

It is incredibly difficult to get investors to fund a second round of development for a product that made it to market and still failed.

You might say this is an opportunity for the government to step in as investor, but they have little interest, knowing that they could use the same money to save many more lives in other areas.